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Objective To compare standard (native tissue) repair with
synthetic mesh inlays or mesh kits.
Design Randomised controlled trial.
Setting Thirty-three UK hospitals.
Population Women having surgery for recurrent prolapse.
Methods Women recruited using remote randomisation.
Main outcome measures Prolapse symptoms, condition-specific
quality-of-life and serious adverse effects.
Results A Mean Pelvic Organ Prolapse Symptom Score at 1 year
was similar for each comparison (standard 6.6 versus mesh inlay
6.1, mean difference [MD] 0.41, 95% CI 2.92 to 2.11: standard
6.6 versus mesh kit 5.9, MD 1.21 , 95% CI 4.13 to 1.72) but
the confidence intervals did not exclude a minimally important
clinical difference. There was no evidence of difference in any
other outcome measure at 1 or 2 years. Serious adverse events,
excluding mesh exposure, were similar at 1 year (standard 7/55
[13%] versus mesh inlay 5/52 [10%], risk ratio [RR] 1.05 [0.66–
1.68]: standard 3/25 [12%] versus mesh kit 3/46 [7%], RR 0.49
[0.11–2.16]). Cumulative mesh exposure rates over 2 years were 7/52
(13%) in the mesh inlay arm, of whom four women required
surgical revision; and 4/46 in the mesh kit arm (9%), of whom
two required surgical revision.
Conclusions We did not find evidence of a difference in terms of
prolapse symptoms from the use of mesh inlays or mesh kits in
women undergoing repeat prolapse surgery. Although the sample
size was too small to be conclusive, the results provide a
substantive contribution to future meta-analysis.
Keywords Pelvic organ prolapse, randomised controlled trial,
repeat surgery, synthetic mesh.
Tweetable abstract There is not enough evidence to support use
of synthetic mesh inlay or mesh kits for repeat prolapse surgery.
Linked article This article is commented on by K Propst, p. 1014
in this issue. To view this mini commentary visit https://doi.org/
10.1111/1471-0528.16241.
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Introduction
Mesh use for prolapse surgery is controversial. Government
policy is changing in the light of increased evidence of
adverse effects.1 In women having a first prolapse repair,
Trial registration: Controlled-Trials.com number ISRCTN60695184
**A list of the PROSPECT study group members is given in Appendix 11.
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our own multicentre randomised controlled trial (RCT)
PROSPECT, set in the UK,2 demonstrated in the short
term, at 2 years, that more than 30% of women still
reported either ‘something coming down’ or had anatomi-
cal prolapse extending beyond the hymen, irrespective of
the use of mesh inlay or biological graft to reinforce the
surgery. As a result of the findings from this trial, augmen-
tation is no longer recommended for a first repair.1
However, Olsen et al.3 showed that 30% of women who
have had one prolapse or incontinence operation required
at least one more procedure, and the time intervals
between repeat procedures decreased with each successive
repair. This study failed to differentiate between repeat sur-
gery for a recurrence in the same compartment and pri-
mary surgery for a de novo prolapse in another
compartment, or new continence procedures.4 Nevertheless,
Olsen et al.’s study suggests that a third of women would
eventually undergo at least one more procedure and some
would require a third or fourth one.3
Our study was preceded by priority assessment based on
the relevant Cochrane review5 and an Interventional Proce-
dures review which investigated the use of mesh for women
having anterior and/or posterior vaginal wall prolapse sur-
gery.6 These and other findings were presented to the Inter-
ventional Procedures Advisory Committee (IPAC) in
January 2008 and their guidance published.7 The commit-
tee recommended that mesh should be used only under
special arrangements for clinical governance, consent and
audit or research: hence, the PROSPECT Study was funded
to fill the evidence gap.
We therefore compared, in an RCT, the effect of mesh
inlay or mesh kit with native tissue repairs in women who
had already experienced at least one failed previous pro-
lapse repair in the same compartment.
We focused on those high-risk women whose specific
compartment prolapse surgery had already failed, to try to
reduce the chance that they would require further prolapse
surgery. After consultation with gynaecologists and experts
from specialist societies, we chose to compare mesh kits as
well as mesh inlays with standard (native tissue) repairs,
based on the scarcity of data about the safety and efficacy
of mesh kits but their perceived potential to provide better
support due to their method of insertion.
Methods
Participants
Women listed for transvaginal repair of an anterior and/or
posterior prolapse were eligible if at least one of the compart-
ments requiring surgery had been repaired previously.
Women could have concomitant uterine, vault or continence
surgery. Women under the care of 59 gynaecologists from 33
UK centres were enrolled into the trial between January 2010
and August 2013. All women provided written informed
consent. The study was funded by the National Institute for
Health Research Health Technology Assessment Programme
(Project Number 07/60/18). The funder (through their peer
review and funding board review process) approved the
study proposal but had no role in the collection, analysis or
interpretation of data, or writing of the report.
Randomisation
A remote web-based computer-generated randomisation
system at the Centre for Healthcare Randomised Trials
(CHaRT, University of Aberdeen, UK) was used for group
allocation. We report two trials: the Mesh Inlay Trial com-
pared standard (native tissue) repair with mesh inlay; and
the Mesh Kit Trial compared standard repair with mesh
kit. Not all gynaecologists offered all treatment options due
to preferences or locally available resources. Therefore,
women were randomised in three strata: Stratum A
included women randomised to one of all three treatment
options, standard repair, mesh inlay and mesh kit (in a
1:1:2 ratio); Stratum B compared standard repair with
mesh inlay (in a 1:1 ratio); Stratum C compared standard
repair with mesh kit (in a 1:2 ratio). Randomisation was
unbalanced in the Mesh Kit Trial in favour of mesh kits to
account for the number of surgeons who were trained in
their use, in order to ensure adequate numbers in the
groups. Because the analyses were carried out separately for
each trial, data from some women in the standard repair
group from Stratum A were included in both trials.
The minimisation algorithm included: age (<60 years or
≥60); planned prolapse repair (anterior, posterior or both);
planned concomitant urinary continence procedure or not;
planned concomitant upper vaginal prolapse procedure or
not; and operating surgeon.
Further details of participants, masking and interventions
are provided as online Supporting Information.
Outcomes
Women were followed up at 6 months, and 1 and 2 years
after surgery by postal questionnaire and were clinically
examined at 1 year.8
We used a wide and comprehensive panel of validated
core outcomes relevant to women, focusing primarily on
women’s symptoms. These were based on internationally
agreed terminology and recommended core outcomes.4
The primary outcome was women’s report of prolapse
symptoms at 1 year after surgery using the Pelvic Organ
Prolapse Symptom Score (POP-SS), a validated measure
which has been shown to be sensitive to change after treat-
ment.9 The POP-SS contains items relating to frequency of
seven prolapse symptoms in the previous 4 weeks: each
item is scored from 0 (never) to 4 (all of the time): the
total score thus ranges from 0 to 28.
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Secondary outcomes included prolapse-specific quality-
of-life measured using a visual analogue scale (VAS) and
generic quality of life based on the EQ-5D-3L,10 and an
assessment of overall global improvement in symptoms
(PGI-I).11 Bladder, bowel and sexual function were mea-
sured using validated or adapted International Consultation
on Incontinence Questionnaires (ICIQ).12 Objective mea-
surement of prolapse stage utilised the POP-Q system.8
Adverse events, need for readmission/further treatment
for adverse effects or prolapse recurrence were reported by
surgeons or women and verified by Study Office staff from
a second source when possible. Adverse events and compli-
cations of surgery were recorded using the IUGA/ICS com-
plications classification which includes type, severity, time
of occurrence and site.13,14 Serious adverse events were
defined using standard classification.15
All definitions are in keeping with the recommendations
of IUGA, ICS and ICI.4,12-14,16 The full Protocol is available
on the funder’s website.17
Statistical analysis
The main analysis was conducted on an intention-to-treat
basis (whereby women with observed outcome data
remained in their allocated group). We did not follow up
randomised women who did not receive any surgery. We
made two comparisons: standard repair versus mesh inlay
(Mesh Inlay Trial, data from women in Strata A and B)
and standard repair versus mesh kit (Mesh Kit Trial, from
Strata A and C) (Figure S1). Study analyses were con-
ducted according to a prespecified statistical analysis plan,
using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA).
All outcome measures were presented as summaries using
descriptive statistics (mean and standard deviation for con-
tinuous measures, and proportion for ordinal and dichoto-
mous measures) and comparisons between randomised
groups were analysed separately at 6 months and 1 and
2 years using generalised linear models. Models were
adjusted for minimisation covariates, baseline measures
where appropriate, and randomisation stratum. Continuous
outcomes were analysed using linear mixed models, with sur-
geon fitted as a random effect. POP-Q stage and PGI-I were
analysed using ordinal logistic regression (proportional odds
models with cumulative logits). Dichotomous outcomes were
analysed using log-binomial regression. Estimates of treat-
ment effect size were mean differences in the linear mixed
models (including the analysis of the POP-SS), odds ratios in
the ordinal models and risk ratios in the binary models. For
all estimates, 95% confidence intervals were calculated.
Sample size
Women were recruited opportunistically alongside those
having a primary repair.2 Based on the assumption that 30%
of women requiring an anterior and/or posterior repair
would receive a secondary or subsequent operation,3 we
expected that approximately 1240 women having secondary
surgery would be available during the recruitment period for
the primary trial.2 Of those available, it was estimated that
50% (620 women) would agree to be randomised.
Pilot data indicated that women having secondary
repairs had worse symptoms at baseline than women hav-
ing their first repair (A. Elders & C. Glazener, unpubl
data).18 We considered it biologically plausible that these
women might show a larger benefit from surgical treatment
than would women having their first repair. We therefore
calculated that, with an expected sample size of 620, it
would be possible to detect, with 90% power and alpha
equal to 0.025, a standardised effect size of 0.38, which
equates to three points on the POP-SS scale (assuming a
standard deviation of 8 units).
Results
Between January 2009 and August 2013, 396 women were
found to have recurrent prolapse of the same compartment
and were therefore potentially eligible for this trial. How-
ever, only 155 (39%) agreed to be randomised, of whom
154 were included in the analyses.19
Baseline characteristics and intervention received
The flow of women through the study is shown in the
CONSORT diagram (Figure 1), in line with recommenda-
tions of the Consolidated Standards of Reporting Trials.20
Women in the randomised groups were comparable at
baseline and all were symptomatic based on at least one
symptom on the POP-SS (Table S1). Two women did not
receive surgery (Figure 1). Most women received their
planned surgery (Figure 1).
In the standard repair group, more women (27% in the
Mesh Inlay Trial and 20% in the Mesh Kit Trial) had a com-
bined anterior/posterior repair than in the other two groups
(synthetic mesh inlay 14% and mesh kit 13%; Table S2).
Concomitant surgery included vaginal hysterectomy, which
occurred in 7%/12% (respectively) of the standard repair
groups, 8% with synthetic mesh inlay and 9% with mesh kit.
A concomitant vault repair was more common in the native
tissue group (25%/28%) compared with 10% in mesh inlay
group and 13% in the mesh kit group. Finally, vaginal con-
comitant continence procedures were performed in 7%/8%
of the native tissue repairs and in 4% of the mesh inlays; no
continence procedures were performed with mesh kits.
Clinical symptoms and quality of life at follow up
Women’s reports of prolapse symptoms (POP-SS) were less
than half of the preoperative level (mean score before sur-
gery 14.4 [SD 5.4], at 6 months 5.9 [5.7], at 1 year 6.3 [6.0],
at 2 years 5.3 [5.3]) (Tables 1, S3 and S4). The improvement
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Upper compartment only 215
Eligible women 396
Declined randomisation 241 b
RANDOMISED 155
Post randomisation exclusions 1c
INCLUDED IN ANALYSIS 154 d
MESH INLAY TRIAL e MESH KIT TRIAL e
107 71
Treatment arm Standard Mesh inlay Standard Mesh kit
55 52 25 46
No surgery 0 (0%) 1 (2%) 0 (0%) 1 (2%)
Received surgery 55 (100%) 51 (98%) 25 (100%) 45 (98%)
Standard repair 49 (89%) 9 (18%) 20 (80%) 4 (9%)
Synthetic mesh 2 (4%) 37 (73%) 1 (4%) 17 (16%)
Mesh kit 0 (0%) 2 (4%) 0 (0%) 31 (69%)
Biological graft 1 (2%) 0 (0%) 1 (4%) 1 (2%)
Other surgery f 3 (5%) 3 (6%) 3 (12%) 2 (4%)
Baseline questionnaire 54 (98%) 50 (96%) 24 (96%) 43 (93%)
6 month questionnaire 50 (91%) 47 (90%) 22 (88%) 43 (93%)
Withdrawals within 6 months 0 (0%) 0 (0%) 0 (0%) 0 (0%)
Deaths within 6 months 0 (0%) 0 (0%) 0 (0%) 0 (0%)
12 month 10 outcome 49 (89%) 44 (85%) 21 (84%) 44 (96%)
12 month 20 outcome 46 (84%) 39 (75%) 21 (84%) 41 (89%)
12 month clinic assessment 46 (84%) 44 (85%) 21 (84%) 38 (83%)
Withdrawals within 12 months 1 (2%) 0 (0%) 0 (0%) 0 (0%)
Deaths within 12 months 1 (2%) 0 (0%) 1 (4%) 1 (0%)
24 month questionnaire 43 (78%) 39 (75%) 20 (80%) 39 (85%)
Withdrawals within 24 months 1 (2%) 3 (6%) 0 (0%) 2 (4%)
Deaths within 24 months 1 (2%) 0 (0%) 1 (4%) 0 (0%)
Footnotes
a 655 women were ineligible or declined recruitment to PROSPECT after screening: No 
prolapse/changed mind about needing surgery (117); Removed from waiting list/unfit for 
surgery (45); Unable to give informed consent (32); Unable to complete questionnaires (16); 
Not interested in participation in study/unknown (413); Other reasons for non-recruitment  
(including ‘psychological or family problems’, ‘not clinically or medically suitable to take part 
in a research study’ and ‘consultant wished to decide procedure’) (32).
b 241 women declined randomisation: 
’Clinical decision’ includes ‘wanted to use mesh’, ‘did not want to use mesh’ and ‘other 
clinical reason’ (133); 
‘Participant decision’ includes ‘wanted mesh’, ‘did not want mesh’ ‘wanted surgeon to 
decide’ and ‘did not want to be randomised’ (96)
‘Other’ reasons’ include ‘mesh unavailable’, ‘operating surgeon not trained in mesh 
inlays/kits’, ‘theatre time issues’ and ‘not recorded’ (12)
c Post randomisation exclusion:  1 woman had secondary prolapse surgery after consenting 
but prior to randomisation.  She was followed up the cohort study (CC2).  
d 56 randomised women were included in the standard repair arm, 52 in the synthetic mesh 
inlay arm and 46 in the synthetic mesh kit arm (total 154).  24 women in Stratum A were 
included in both the Mesh Inlay and Mesh Kit Trials, such that there were a total of 55 
women in the standard repair arm of the Mesh Inlay Trial and 25 women in the standard 
repair arm of the Mesh Kit Trial.  The numbers of participating women by individual strata 
are set out in Supplementary Figure 1. 
e Percentages shown represent the number of women as a proportion of those included in the 
analysis.
f Other surgery includes women who did not have either an anterior or posterior repair, but 
did receive one or more of:  tape for urinary incontinence, vaginal hysterectomy or 
suspension, cervical amputation, vault repair
Figure 1. CONSORT diagram
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Table 1. Clinical symptoms and quality of life outcomes at 1 and 2 years: (a) Mesh Inlay Trial, (b) Mesh Kit Trial
(a) Mesh Inlay Trial: Standard versus Synthetic Mesh Inlay
Standard Mesh Inlay Est. 95% CI P-value
1-year outcomes N = 49 N = 44
POP-SS at 1 year 6.6 (6.0) 49 6.1 (6.4) 44 0.41 2.92 to 2.11 0.747
Prolapse-related QoL scorea 2.5 (2.9) 47 3.0 (3.4) 44 0.43 0.90 to 1.75 0.522
Symptomatic prolapseb 81.6% 40/49 88.6% 39/44 1.05 0.82–1.33 0.714
Women with any report of SCDc 44.9% 22/49 40.9% 18/44 0.91 0.58–1.43 0.680
Urinary incontinence (severe)d 2.2% 1/46 12.8% 5/39 5.52 0.68–44.77 0.110
Fecal incontinence (any)e 26.1% 12/46 43.6% 17/39 1.41 0.84–2.35 0.190
ICI Vaginal Symptoms Score 8.3 (7.4) 44 7.9 (8.6) 37 1.29 4.99 to 2.42 0.487
Dyspareunia (severe)f 0.0% 0/18 13.0% 3/23 n/a n/a n/a
EQ-5D-3L score at 1 year 0.74 (0.30) 50 0.83 (0.22) 43 0.03 0.07 to 0.14 0.519
PGI-I at 1 yearg 76.7% 33/43 81.6% 31/38 1.18 0.47–2.95 0.731
2-year outcomes N = 43 N = 39
POP-SS at 2 years 4.8 (5.0) 43 5.4 (5.5) 39 0.58 1.68 to 2.84 0.607
Prolapse-related QoL scorea 1.7 (2.4) 41 2.4 (2.7) 36 0.38 0.84 to 1.60 0.529
Symptomatic prolapseb 83.7% 36/43 82.1% 32/39 1.00 0.80–1.24 0.981
Women with any report of SCDc 30.2% 13/43 25.6% 10/39 0.78 0.38–1.60 0.497
Urinary incontinence (severe)d 7.1% 3/42 10.3% 4/39 1.64 0.38–7.07 0.507
Faecal incontinence (any)e 27.9% 12/43 44.7% 17/38 1.35 0.74–2.47 0.326
ICI Vaginal Symptoms Score 7.3 (7.6) 39 7.9 (7.8) 37 0.64 4.56 to 3.28 0.742
Dyspareunia (severe)f 0.0% 0/15 4.5% 1/22 n/a n/a n/a
EQ-5D-3L score at 2 years 0.76 (0.29) 42 0.82 (0.19) 38 0.00 0.11 to 0.11 0.975
PGI-I at 2 yearsg 81.0% 34/42 74.4% 29/39 1.01 0.41–2.49 0.974
(b) Mesh Kit Trial: Standard versus Mesh Kit
Standard Mesh Kit Est. 95% CI P-value
1-year outcomes N = 21 N = 44
POP-SS at 1 year 6.6 (5.5) 21 5.9 (5.3) 44 1.21 4.13 to 1.72 0.408
Prolapse-related QoL scorec 2.0 (2.6) 21 2.3 (2.8) 43 0.31 1.99 to 1.36 0.706
Symptomatic prolapsea 90.5% 19/21 86.4% 38/44 0.93 0.67–1.28 0.638
Women with any report of SCDb 57.1% 12/21 36.4% 16/44 0.57 0.29–1.10 0.094
Urinary incontinence (severe)d 0.0% 0/21 10.0% 4/40 n/a n/a n/a
Faecal incontinence (any)e 28.6% 6/21 39.0% 16/41 1.59 0.57–4.49 0.378
ICI Vaginal Symptoms Score 6.7 (6.0) 18 5.8 (4.8) 35 2.82 6.67 to 1.02 0.143
Dyspareunia (severe)f 0.0% 0/6 5.6% 1/18 n/a n/a n/a
EQ-5D-3L score at 1 year 0.79 (0.27) 22 0.83 (0.19) 41 0.05 0.07 to 0.17 0.411
PGI-I at 1 yearg 77.8% 14/18 87.2% 34/39 0.58 0.18–1.90 0.372
2-year outcomes N = 20 N = 39
POP-SS at 2 years 3.9 (4.4) 20 5.4 (5.3) 39 0.65 2.20 to 3.50 0.642
Prolapse-related QoL scorec 1.5 (2.6) 18 2.5 (2.7) 37 0.32 1.45 to 2.09 0.712
Symptomatic prolapsea 85.0% 17/20 76.9% 30/39 0.92 0.63–1.33 0.655
Women with any report of SCDb 25.0% 5/20 35.9% 14/39 1.17 0.47–2.87 0.739
Urinary incontinence (severe)d 5.0% 1/20 10.3% 4/39 1.58 0.20–12.48 0.663
Faecal incontinence (any)e 30.0% 6/20 38.5% 15/39 1.04 0.47–2.31 0.918
ICI Vaginal Symptoms Score 6.1 (6.2) 17 7.9 (7.4) 36 0.08 4.91 to 5.08 0.973
Dyspareunia (severe)f 0.0% 0/6 0.0% 0/16 n/a n/a n/a
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at 1 year was maintained at 2 years, with respect to all the
prolapse and quality of life outcomes measured.
In the Mesh Inlay Trial, the mean difference (MD) in
the POP-SS score at 1 year for standard repair (mean 6.6,
SD 6.0) versus synthetic mesh inlay (mean 6.1, SD 6.4),
based on combined data from women in Stratum A (three-
way randomisation) and Stratum B (two-way randomisa-
tion), was 0.41 (95% CI 2.92 to 2.11).
In the Mesh Kit Trial, the MD in the POP-SS score at
1 year for standard repair (mean 6.6, SD 5.5) versus mesh kit
(mean 5.9, SD 5.3), based on combined data from women in
Stratum A (three-way randomisation) and Stratum C (two-
way randomisation), was 1.21 (95% CI 4.13 to 1.72).
At 2 years, the study found that women having a mesh
kit had a better generic QoL score, measured with EQ-5D-
3L, than did those who had a standard repair (MD 0.13
[95% CI 0.02–0.25]: P = 0.025; Table 1).
The other key symptoms of pelvic floor dysfunction –
urinary, faecal, vaginal and sexual symptoms – are pre-
sented in Tables 1 and S4. Although there was a decrease
in the proportion of women with severe urinary inconti-
nence after surgery, there was no difference between the
randomised groups in either the Mesh Inlay Trial or the
Mesh Kit Trial in respect of any of the urinary outcomes
measured. Frequency of bowel movement and constipation
were largely unchanged after prolapse surgery. There were
no differences between the randomised groups in respect of
any of the bowel outcomes measured.
Many women reported improvements in their vaginal and
sexual function outcomes after surgery: this was evident
from a reduction of the ICI-Q Vaginal Symptoms score
(Table 1). After surgery, fewer women cited prolapse symp-
toms as a reason for not having a sex life (around 35%
before surgery, versus around 10% after). Four women had
severe dyspareunia at 1 year (Mesh Inlay group = 3, Mesh
Kit group = 1), but only one at 2 years (Mesh Inlay group).
However, there were no statistically significant differences
between the randomised groups in respect of any of the vagi-
nal or sexual symptom outcomes measured.19
Satisfaction with treatment
Most women reported that their prolapse symptoms were
very much or much better than before surgery, with no sta-
tistically significant differences between the groups in either
trial (Table S4).
Objective outcomes
At 1 year, 83% of women attended for clinical review.
Objective measurement showed improvement in each of
the three prolapse compartments. The proportion of
women with the leading prolapse edge beyond the hymen
(POPQ >0 cm) reduced substantially. In the Mesh Inlay
Trial, the difference between groups based on clinician’s
estimates of stage was RR 0.75, 95% CI 0.33–1.68,
P = 0.479, and the proportion with more severe objective
prolapse defined as ‘leading edge of the prolapse at >0 cm
beyond the hymen on POP-Q’ was 14% in each group (RR
0.59, 95% CI 0.18–1.92, P = 0.380 (Table 2).
In the Mesh Kit Trial, women who had a standard repair
were more likely to have prolapse compared with those
who were randomised to mesh kit based on clinician’s esti-
mates of all stages (RR 0.24, 95% CI 0.07–0.83, P = 0.024;
Table 1. (Continued)
(b) Mesh Kit Trial: Standard versus Mesh Kit
Standard Mesh Kit Est. 95% CI P-value
EQ-5D-3L score at 2 years 0.76 (0.29) 20 0.87 (0.14) 38 0.13 0.02–0.25 0.025
PGI-I at 2 yearsg 85.0% 17/20 89.5% 34/38 1.53 0.47–4.96 0.478
Continuous variables presented as mean (SD). n/N, dichotomous variables presented as % n/N.
Effect size: For all negative continuous outcomes, e.g. POP-SS, a positive effect size favours standard repair. For all positive continuous outcomes,
e.g. EQ5D, a positive effect size favours the synthetic/mesh kit. For all negative dichotomous outcomes, e.g. urinary incontinence, an effect size
more than 1 favours standard repair. For all positive dichotomous outcomes e.g. prolapse better, an effect size more than 1 favours the synthetic/
mesh kit.
aQuality of life due to prolapse symptoms measured as ‘overall interference of prolapse symptoms with everyday life’ using a visual analogue scale
(VAS); score range from 0 (not at all) to 10 (a great deal).
bSymptomatic defined as POP-SS >0.
cWomen with any report of something slipping down.
dSevere urinary incontinence defined as ICIQ-SF score 13–21.
eFecal incontinence of solid or liquid stool: any = occasionally or more.
fSevere dyspareunia defined as ‘Do you have pain when you have sexual intercourse: ‘a lot’. Denominators confined to sexually active women.
gPGI-I Patient-Global impression of Improvement = very much or much better (versus a little better, no change, a little worse, much worse, very
much worse). Effect sizes are odds ratios estimated from ordinal logistic regression.
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Table 2). However, for more severe objective prolapse (de-
fined as above), 3/18 (17%) of standard repair women had
residual prolapse compared with none of 35 women after a
mesh kit procedure.
Readmission, adverse effects and further treatment
Five women were readmitted in the first 6 months after
surgery (Standard group = 2, Mesh Inlay group = 3;
Table 3). Two subsequent readmissions were for revision of
prolapse surgery (Fenton’s operation)—one in the Mesh
Kit group and one in the Mesh Inlay group.
Individual serious adverse events were rare, the most
common being infection, pain and urinary retention
(Table S5). In the first year, the number of women with
serious non-mesh adverse events were as follows: Mesh
Inlay Trial: standard 7/55, 12.7% versus mesh inlay 5/52,
9.6%, RR 1.05, 95% CI 0.66–1.68, P = 0.831; Mesh Kit
Trial: standard 3/25, 12.0% versus mesh kit 3/46, 6.5%, RR
0.49, 95% CI 0.11–2.16, P = 0.345. No women experienced
cystotomies or bladder perforations during either mesh
insertion or native tissue repair. One woman, in the mesh
kit arm, required a blood transfusion. Non-serious adverse
events were also rare (Table S6).
In the first 2 years, 7/52 women had vaginal mesh expo-
sure in the mesh inlay arm (13%), of whom four required
surgical revision; and 4/46 women had vaginal mesh expo-
sure in the mesh kit arm (8%), of whom two needed surgi-
cal revision. Hence in total, six women needed further
surgery to address an area of mesh exposure (all but one
<1 cm2) 2 years after surgery. There were no reports of
mesh perforation of the bladder or bowel at insertion but
one woman in the Mesh Inlay Trial experienced a bowel
perforation during mesh removal. The other mesh expo-
sures were managed conservatively by observation, topical
estrogens or cautery.
At 2 years after surgery, around 20% of women who had
a standard repair required further treatment for prolapse
compared with 11% who had a mesh inlay and 5% who
had a mesh kit (Table 3): however, there was no statistical
difference between the randomised groups.
Discussion
Main findings
There were no statistically significant differences at 1 year in
the primary clinical outcomes after prolapse surgery using
native tissue, polypropylene non-absorbable mesh or a mesh
kit to reinforce the repair in either trial. The uncertainty
around this finding is reflected in the wide confidence inter-
vals around the primary outcome (POP-SS) at 1 year (RR
0.41, 95% CI 2.92 to 2.11 in the Mesh Inlay Trial and
RR 1.21, 95% CI 4.13 to 1.72 in the Mesh Kit Trial).
Women in the Mesh Kit Trial were less likely to have pro-
lapse beyond Stage 2 at 1 year and had a higher (better)
EQ-5D-3L score at 2 years. However, these may have been
chance findings and their clinical significance is uncertain as
there were no differences in any other subjective outcomes
between the randomised groups at any time point.
The overall incidence of non-mesh-related serious
adverse events was around 10% and comprised primarily
pain, infection and urinary retention. As women could only
have a mesh-related complication if they received mesh,
Table 2. Objective measures of prolapse at 1 year
One-year
review
Mesh Inlay Trial Mesh Kit Trial
Standard Mesh Inlay Est. 95% CI P-value Standard Mesh kit Est. 95% CI P-value
n = 46 n = 44 n = 21 n = 38
POP-Q
Ba 1.4 (1.5) 42 1.4 (1.4) 41 0.22 0.80 to 0.36 0.445 1.2 (1.9) 19 1.8 (1.0) 35 0.74 1.4 to 0.10 0.026
C 5.6 (2.4) 41 6.2 (1.5) 41 0.61 1.38 to 0.16 0.119 5.1 (2.7) 18 6.0 (1.8) 33 0.65 1.6 to 0.3 0.173
Bp 1.8 (1.6) 41 2.2 (1.1) 41 0.49 1.08 to 0.10 0.099 1.9 (1.7) 18 2.2 (0.8) 34 0.38 1.2 to 0.4 0.317
Tvl 7.7 (1.2) 43 7.9 (1.4) 42 0.09 0.47 to 0.65 0.746 7.7 (1.0) 19 8.1 (1.2) 33 0.64 0.1 to 1.20 0.028
Overall POP-Q stage
Stage 0 13.6% 6/44 7.0% 3/43 0.75 0.33–1.68 0.479 10.5% 2/19 14.3% 5/35 0.24 0.07–0.83 0.024
Stage 1 36.4% 16/44 44.2% 19/43 31.6% 6/19 45.7% 16/35
Stage 2 40.9% 18/44 46.5% 20/43 42.1% 8/19 40.0% 14/35
Stage 3 9.1% 4/44 2.3% 1/43 15.8% 3/19 0.0% 0/35
Stage 4 0.0% 0/44 0.0% 0/43 0.0% 0/19 0.0% 0/35
Stage 2b,
3 or 4a
14.0% 6/43 14.0% 6/43 0.59 0.18–1.92 0.380 16.7% 3/18 0.0% 0/35 n/a n/a n/a
% n/N or mean (SD).
aObjective prolapse: stage 2b, 3, or 4, defined as leading edge beyond the hymen (>0 cm) when POP-Q data available.
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the total numbers for this outcome are small, with six
women needing further surgery to address mesh exposure.
Strengths and limitations
PROSPECT is rare in being one of the few RCTs in the
field to distinguish rigorously between primary and sec-
ondary surgery. Unfortunately, our secondary trials on
their own did not attain sufficient power to detect a differ-
ence. In future, studies should report prolapse surgery trials
using the subgroups of Primary and Secondary (the latter
defined as ‘repeat surgery in the same compartment’).
Another strength was the pragmatic reflection of actual
practice in the UK. We included surgeons from a large
number of hospital settings. It was not possible for all sur-
geons to randomise women between all three options, but
the analysis by strata accommodated this.
Our secure and effective randomisation programme
ensured that women were comparable at baseline and that
concomitant surgery and other confounding variables were
accounted for. We used validated outcome measures to
measure women’s symptoms of pelvic floor dysfunction.
We captured a wide range of adverse effects and made
efforts to verify these from alternative sources when possi-
ble. Essential missing data were actively sought from the
women. Participants, outcome assessors and data entry
clerks were blinded to randomisation as far as possible.
Table 3. Readmission, adverse effects and further treatment
Mesh Inlay Trial: Standard versus Synthetic Mesh Inlay Mesh Kit Trial: Standard versus Mesh Kit
Standard Mesh Inlay Est. 95% CI P-value Standard Mesh Kit Est. 95% CI P-value
N = 43 N = 38 N = 20 N = 39
Readmissions
0–6 months
4.0% 2/50* 6.4% 3/47** 1.76 0.30–10.37 0.532 0% 0/22 0% 0/43 n/a n/a n/a
Readmissions
6–12 months
0% 0/49 0% 0/44 n/a n/a n/a 0% 0/21 2.3% 1/44*** n/a n/a n/a
Readmissions
12–24 months

























14.0% 6/43 7.9% 3/38 0.49 0.14–1.82 0.290 20.0% 4/20 2.6% 1/39 0.13 0.02–1.12 0.063
Same compartment 11.6% 5/43 2.6% 1/38 0.22 0.03–1.83 0.162 15.0% 3/20 2.6% 1/39 0.28 0.03–2.92 0.285
Different compartment 2.3% 1/43 5.3% 2/38 1.74 0.16–18.79 0.647 5.0% 1/20 0.0% 0/39 n/a n/a n/a




18.6% 8/43 10.5% 4/38 0.45 0.15–1.40 0.170 20.0% 4/20 5.1% 2/39 0.27 0.05–1.33 0.107
*Reasons for readmission (Standard; 0–6 months): infection (2).
**Reasons for readmission (Synthetic; 0–6 months): retention (1), adhesions (1), constipation (1).
***Reasons for readmission (Kit; 6–12 months): Revision prolapse surgery (Fenton’s) (1).
****Reasons for readmission (Synthetic; 12–24 months): Revision prolapse surgery (Fenton’s) (1).
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Limitations of our study should be acknowledged. The
complex design of the study (with three interventions
across three strata) generated multiple comparisons, partic-
ularly across the secondary outcomes, so care must be
taken not to over-interpret the results, as it is likely that
some differences may have occurred by chance.
Furthermore, we identified fewer women than expected
(396 rather than 1240) because of our more rigorous defi-
nition of repeat surgery (same compartment rather than
any compartment, 30%).1 In addition, fewer women than
expected were randomised (39% rather than 50%): this was
more often due to a clinical decision rather than the
women’s choice (54% versus 39%). This resulted in fewer
women than estimated (155 rather than 620) being ran-
domised. Thus, we were not able to recruit to the sample
size that would have given us enough power to identify a
difference of three points on the POP-SS.
We and other researchers have suggested that prolapse
beyond the hymen (>0 cm on POP-Q) is a sign of severe
objective failure.21 However, we recognise that women with
worse anatomical findings may not have symptoms and,
vice versa, women with an objective ‘cure’ may still have
prolapse symptoms.
Longer follow up is required: the average time to a
repeat operation (in any compartment) is around
12 years.1 While we did not identify differences in the
repeat surgery rate between the groups, it is likely that
2 years is too short a time scale to provide a definitive
answer. Both the natural history of prolapse and the long-
term ongoing tissue interactions with polypropylene indi-
cate that it is important that trials pursue longer term fol-
low up of outcomes and complications, ideally over
12 years.3 We have commenced follow up of the PRO-
SPECT women for at least 6 years after surgery and also
plan electronic data linkage to capture outcomes from
non-responders about further admission for prolapse
surgery.
Interpretation (in light of other evidence)
The most recent Cochrane review22 identified 37 trials of
mesh or graft in women having anterior, posterior or apical
prolapse surgery. Only two of those RCTs published sepa-
rate data from women having repeat surgery for recurrent
anterior or posterior prolapse,23,24 although most trials
included some such women. Both relevant RCTs compared
native tissue repair with a mesh kit (Prolift Gynaecare,
inserted with trochars, which is no longer available). Alt-
man reported only a composite failure rate at 1 year in 53
women (20/25 versus 14/28).23 Withagen reported long-
term prolapse symptoms at 7 years in up to 142 women
(sensation of bulge at 7 years: 17/76 with native tissue ver-
sus 14/66 with mesh kit).24 Although anatomical failure
rates were less in the mesh group (47/67 versus 28/53 at
7 years), there was little difference in the further prolapse
surgery rate (11/69 versus 14/56). The mesh exposure rate
in the mesh kit group (42% at 7 years) was high and 54%
were symptomatic, while a third of the women required
surgical revision. Neither trial was conclusive.
Meta-analysis of the PROSPECT data with the two trials
examining mesh kits showed that more women had pro-
lapse symptoms with native tissue (68%) than with mesh
kits (42%) in the first year (RR 1.56, 95% CI 1.11–2.18)
but this difference did not persist in the longer term (23
versus 27%: RR 0.92, 95% CI 0.55–1.52). More women had
persistent objective prolapse at 1 year (40 versus 7%, RR
4.97, 95% CI 2.52–9.81) but this was not reflected in repeat
prolapse surgery rates (17 versus 18%, RR 0.85, 95% CI
0.46–1.54) at up to 7 years’ follow up. Four of 52 women
required surgery for mesh exposure after a mesh inlay, and
9/99 women after a mesh kit, although many mesh expo-
sures were small and asymptomatic.
PROSPECT was the only trial to compare native tissue
repairs with synthetic mesh inlays.
In any case, in the light of increased evidence of adverse
effects, it is unlikely that further trials of mesh will be con-
ducted.1
Conclusions
Based on the evidence available in this trial, we are unable
to say whether a mesh inlay or a mesh kit confers more
benefit to women having a repeat prolapse repair than
native tissue surgery in the first 2 years after surgery. Some
women required an additional surgical procedure to
remove exposed mesh, which may be considered to be an
unnecessary risk. However, long-term follow up may reveal
whether the excess risks are offset by a potential decrease
in the need for repeat surgery, which in itself is associated
with higher risks.
PROSPECT is rare in being one of the few RCTs to dis-
tinguish rigorously between primary and repeat surgery.
We would strongly encourage future studies to use our
approach. Although our trial did not have sufficient power
to demonstrate a statistical difference, the information is
available for meta-analysis with other trials.19 Further long-
term follow up will ultimately determine whether the use
of synthetic mesh in vaginal prolapse repair confers any
long-term benefits in women whose prolapse surgery has
already failed at least once. Large international datasets will
be required to make true progress in this field.
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The PROSPECT study was overseen by an independent
Trial Steering Committee (Henry Kitchener [Chair], Ranee
Thakar [Clinician], Pamela Warner [Statistician], Trish
Emerson [Patient Representative, 2012—present], Catherine
Rodger [Patient Representative, 2010–2012]) and an inde-
pendent Data Monitoring Committee (James Neilson
[Chair], Lucia Dolan [Clinician], Paula Williamson [Statis-
tician], Gill Gyte [Patient Representative]).
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